Printer Friendly

CEPHALON CO-FOUNDER TO JOIN SYMPHONY PHARMACEUTICALS

 PHILADELPHIA, Aug. 17 /PRNewswire/ -- Symphony Pharmaceuticals, Inc. today announced it has appointed Michael E. Lewis, Ph.D., as vice president - research. Dr. Lewis, who co-founded Cephalon, leaves his post as that company's senior director of scientific affairs to join Symphony.
 "Michael will play an invaluable role guiding our research into the regulation of ion currents in the brain. He is not only a high-caliber scientist, but also has an in-depth understanding of the biotechnology industry," said Maria-Luisa Maccecchini, Ph.D., Symphony's founder and CEO. "We are pleased to have such a distinguished and capable individual join our management team."
 Dr. Lewis has more than 20 years experience in pharmaceutical drug research. At Symphony, he will be responsible for discovering novel compounds and bringing Symphony's lead compound for stroke and head trauma into the clinic by year-end.
 At Cephalon, Dr. Lewis guided the company's research strategy and directed its discovery program for IGF-1 in the treatment of amyotrophic lateral sclerosis (Lou Gehrig's disease). He also initiated programs in ischemia, gene therapy and retinopathy. In addition, Dr. Lewis was responsible for Cephalon's roadshow presentations during the company's private and public financings.
 "My experience at Cephalon has provided me with a skill set which I have wanted to apply to a young, promising company," said Dr. Lewis, who will maintain his affliction with Cephalon as a research consultant. "Symphony has offered me a unique opportunity to direct its ion channel research programs at a critical stage of their development. I look forward to taking its programs from the bench to the clinic and playing a major role in Symphony's success."
 Prior to co-founding Cephalon in 1988, Dr. Lewis was principal scientist with Du Pont. Dr. Lewis has a Ph.D. from Clark University where he examined nerve growth factor and recovery of function after brain damage. He was a research fellow at the University of Cambridge and spent two years at the National Institutes of Health and four years at the University of Michigan.
 Symphony, founded in 1992, is a private biopharmaceutical company focusing on the discovery and development of novel drugs to regulate the flow of electricity through ion channels in the brain. The company has targeted its initial drug development efforts on stroke, trauma, depression and addiction. Symphony's technology can also be applied to anxiety, epilepsy, memory loss and learning disabilities as well as Huntington's, Alzheimer's and Parkinson's diseases.
 -0- 8/17/93
 /CONTACT: Maria-Luisa Maccecchini, Ph.D., chief executive officer, of Symphony Pharmaceuticals, Inc., 215-640-4870; or Anthony J. Russo, Ph.D., of Noonan/Russo Communications, 212-696-4455/


CO: Symphony Pharmaceuticals, Inc. ST: Pennsylvania IN: MTC SU: PER

MP-SH -- NY026 -- 3456 08/17/93 10:11 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 17, 1993
Words:445
Previous Article:CONN. UNEMPLOYMENT COMP. REV. BONDS 1993 B EXPECTED 'F-1+' BY FITCH -- FITCH FINANCIAL WIRE --
Next Article:PANEL ON INFLAMMATORY BOWEL DISEASE MEETS TO 'BREAK THE SILENCE' ABOUT DISEASE AFFECTING TWO MILLION AMERICANS
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters